Visit Upsher-Smith at the PPMD 2025 Annual Conference Resource Fair to Learn More About Support Services and Resources Offered for Deflazacort Tablets
Maple Grove, MN – June 16, 2025 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced ... Read More
First and Only Ready-to-Use Vigabatrin Expands Treatment Access for Patients with Infantile Spasms
Maple Grove, MN – May 19, 2025 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that VIGAFYDE™ (vigabatrin) Oral Solution, the first and only ... Read More
Company to Feature First and Only Ready-to-Use Liquid Vigabatrin at Booth #846
Maple Grove, MN – April 4, 2025 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its participation at the 2025 American Academy of Neurology ... Read More
Maple Grove, MN – February 11, 2025 – Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) are pleased to announce the recipients of the 2024 NASPA Excellence in Innovation Award. ... Read More
Maple Grove, MN – December 2, 2024 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its participation at AES 2024, the Annual Meeting of the American Epilepsy Society, from December 6-10, 2024 in Los Angeles, California, ... Read More
Visit Our Booths to Learn More about the Company’s Latest Product Offerings and Promise of Support™ Program
Maple Grove, MN – November 11, 2024 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will attend ... Read More
Taipei, Taiwan, October 25, 2024 Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals
Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors ... Read More
Maple Grove, MN – October 17, 2024 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Olanzapine Tablets, USP, in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg ... Read More
Maple Grove, MN – August 5, 2024 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of TORPENZ™ (everolimus) Tablets in 2.5 mg, 5 mg, 7.5 mg and 10 mg strengths. TORPENZ™ is an ... Read More
Maple Grove, MN – July 1, 2024 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today unveiled its enhanced Promise of Support™ Program – a patient-centered program designed to offer patients, caregivers, and healthcare providers in the rare ... Read More
